Recently, Beijing Jabrehoo medical technology co., LTD. had held a signing ceremony with the United States Illumina in Beijing. The partners had made the strategic cooperation on jointly developing and promoting the assisted reproduction diagnosis methods and solutions based on the new generation sequencing technology . The signing of the cooperation is further evidence that genomics technology will play a more and more important role in the field of assisted reproduction. The investors Peak and Morningside venture capital also attended the  signing ceremony.

As a core part of the third generation of test-tube baby technology, pre-implantation genetic screening (PGS) and pre-implantation genetic diagnosis (PGD) technology have been closely paid attention. In recent years, the new generation sequencing for medical technology revolution has infiltrated in various clinical departments. This time, Beijing Jabrehoo which is the highest market share in the field of national PGS/PGD, and global genomics Illumina technology leader had made the win-win co-operation. It will beneficially promote the development of the whole field of assisted reproduction technology and benefit more patients with infertility.

Fei jia, the Founder, Chairman & General manager of Beijing Jabrehoo, said that, “Jabrehoo is among the first companies that has applied the new generation sequencing technology in the field of PGS and PGD . And it also has won the approval of many experts in the industry. Particularly, we chose to help the construction of the reproductive center platform and jointly explore new technology, this kind of open mode not only help beijing jabreho get rapid development, at the same time also makes clinicians to have a thorough understanding with  platform and technology. Then better application platform technology will serve the masses of patients, this is what we really want to do. The reason why we have been very low-key is that we want to make sure every product stability, every little problem solved, and then let the market to decide our future. And the core of the clinical demand is not innovation, but the stability, accuracy and simplity of detection, and we are the company that provides integrated service platform around the field of assisted reproduction. This cooperation with the leader of the global field of sequencing Illumina, will further promote the performance and solution efficiency of Jabrehoo, a better service to our customers; At the same time, the contract is confirmed that as long as we focus on our work, our team will get customers, partners and investors. "

Jeff Hawkins, Senior Vice President of assisted reproduction and genetic group of Illumina, said in an interview after signing the contract, “we show our big admiration to Beijing Jabrehoo’s dedicated spirit and efficient work style. Illumina is very glad to cooperate with the company, so as to better provide clinical solutions including PGS/PGD of assisted reproduction based on the new generation sequencing. Our vision is to improve human health through interpretation of genome, we have been committed to cooperation with chinese companies which have the same visions.”